He develops novel small-molecule drugs targeting cancer stem cells for treating pancreatic cancer.
BROOKLINE, MA, August 06, 2024 /24-7PressRelease/ -- Dr. Shin Mukai has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Dr. Mukai's motivation for starting the fight against cancer was deeply personal and professional. It stemmed from his encounters with the impacts of cancer on individuals and families, including his own. A seasoned research scientist with a decade and a half of experience in organic synthesis, single-cell mRNA sequencing, flow cytometry, mass cytometry, and animal experiments, he excels as the co-founder, chief executive officer, and chief scientific officer of New Wind Therapeutics L3C, named one of the 50 Leading Companies of the Year in 2024 by The Silicon Review. In this capacity, he develops novel small-molecule drugs targeting cancer stem cells for treating pancreatic cancer. Likewise, Dr. Mukai leverages his considerable expertise to design and direct pre-clinical drug development and contributed to various publications, including "Therapeutic Approaches Targeting Cancer Stem Cells."
Before obtaining his current role with New Wind Therapeutics, Dr. Mukai was a senior scientist specializing in immunology and inflammation research therapeutics for Sanofi and a postdoctoral research fellow at Harvard Medical School and the Keio University School of Medicine. During the early stages of his career, he gained valuable expertise in education, chemistry, and more with the University of Western Australia and Kyoto University. Throughout his career, Dr. Mukai has also published such articles as "Novel Treatment of Chronic Graft-Versus-Host Disease in Mice Using the ER Stress Reducer 4-Phenylbutyric Acid" and "Stable triazolylphosphonate analogues of phosphohistidine". Similarly, he co-patented a novel treatment for chronic graft-versus-host disease by reducing endoplasmic reticulum stress.
An expert in his field, Dr. Mukai holds a Bachelor of Engineering in chemistry and a Master of Engineering in bio-organic chemistry from Kyoto University. Subsequently, he expanded his professional skills and knowledge by completing a PhD in bio-organic chemistry at the University of Western Australia and certifications through The Harvard Clinical and Translational Science Center and Harvard Business School. Driven to remain abreast of changes in the field, Dr. Mukai aligns himself with the Harvard Alumni Entrepreneurs, the Royal Society of Chemistry, the American Chemical Society and the Royal Australian Chemical Institute.
In conjunction with his industry endeavors, Dr. Mukai contributes to his community and fellow industry professionals as a council leader with the U.S.-Japan Council and a PhD career adviser for Intellect Bay. Given his outstanding achievements, he has been named to the Top 100 Magazine's Top 100 Innovators & Entrepreneurs, IndustryWired's 10 Best Entrepreneurs to Look Out in 2024, and Fortune Business Review's 10 Most Innovative CEOs in Business. Additionally, he was honored with the Australian Postgraduate Award from the University of Western Australia and the Top Chief Scientific Officer of the Year Award through the International Association of Top Professionals, which was the highlight of his career. In the coming years, Dr. Mukai aims to develop new anticancer drugs through New Wind Therapeutics L3C.
About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.
# # #